Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
08 2020
Historique:
received: 22 10 2019
accepted: 18 03 2020
pubmed: 30 4 2020
medline: 6 3 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

To determine the risk of cardiovascular disease (CVD), microvascular complications, and mortality in patients with type 2 diabetes who subsequently develop obstructive sleep apnea (OSA) compared with patients with type 2 diabetes without a diagnosis of OSA. This age-, sex-, BMI-, and diabetes duration-matched cohort study used data from a U.K. primary care database from 1 January 2005 to 17 January 2018. Participants aged ≥16 years with type 2 diabetes were included. Exposed participants were those who developed OSA after their diabetes diagnosis; unexposed participants were those without diagnosed OSA. Outcomes were composite CVD (ischemic heart disease [IHD], stroke/transient ischemic attack [TIA], heart failure [HF]), peripheral vascular disease (PVD), atrial fibrillation (AF), peripheral neuropathy (PN), diabetes-related foot disease (DFD), referable retinopathy, chronic kidney disease (CKD), and all-cause mortality. The same outcomes were explored in patients with preexisting OSA before a diagnosis of type 2 diabetes versus diabetes without diagnosed OSA. A total of 3,667 exposed participants and 10,450 matched control participants were included. Adjusted hazard ratios for the outcomes were as follows: composite CVD 1.54 (95% CI 1.32, 1.79), IHD 1.55 (1.26, 1.90), HF 1.67 (1.35, 2.06), stroke/TIA 1.57 (1.27, 1.94), PVD 1.10 (0.91, 1.32), AF 1.53 (1.28, 1.83), PN 1.32 (1.14, 1.51), DFD 1.42 (1.16, 1.74), referable retinopathy 0.99 (0.82, 1.21), CKD (stage 3-5) 1.18 (1.02, 1.36), albuminuria 1.11 (1.01, 1.22), and all-cause mortality 1.24 (1.10, 1.40). In the prevalent OSA cohort, the results were similar, but some associations were not observed. Patients with type 2 diabetes who develop OSA are at increased risk of CVD, AF, PN, DFD, CKD, and all-cause mortality compared with patients without diagnosed OSA. Patients with type 2 diabetes who develop OSA are a high-risk population, and strategies to detect OSA and prevent cardiovascular and microvascular complications should be implemented.

Identifiants

pubmed: 32345651
pii: dc19-2116
doi: 10.2337/dc19-2116
doi:

Banques de données

figshare
['10.2337/figshare.12014598']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1868-1877

Subventions

Organisme : Department of Health
ID : CS-2013-13-029
Pays : United Kingdom

Informations de copyright

© 2020 by the American Diabetes Association.

Auteurs

Nicola J Adderley (NJ)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Anuradhaa Subramanian (A)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Konstantinos Toulis (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Krishna Gokhale (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Thomas Taverner (T)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Wasim Hanif (W)

Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K.

Shamil Haroon (S)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

G Neil Thomas (GN)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Christopher Sainsbury (C)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.

Abd A Tahrani (AA)

Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K. a.a.tahrani@bham.ac.uk.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, U.K.

Krishnarajah Nirantharakumar (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, U.K.
Midlands Health Data Research UK, Birmingham, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH